In the United States, health insurers cover the cost only if a first-degree relative – for example, a woman’s mother – has had a history of breast or ovarian cancer; other women must pay out of pocket. Given the benefits of preventive care, the test has become highly controversial, because its manufacturer, Myriad Genetics, holds a genetic patent that gives it a monopoly – and huge profits – on all testing.